Quizartinib
Hematology
Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QUANTUM-R trial
Ganguly S, Cortes JE, Kramer A, et al.
Transplant Cell Ther. 2021;27(2):153-162.
Edoxaban
Cardiovascular - AF
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF prolongation registry
Renda G, Pecen L, Patti G, et al.
Intern Emerg Med. 2021;16(3):591-599.
Edoxaban
Cardiovascular - AF
Low-dose edoxaban in very elderly patients with atrial fibrillation
Okumura K, Akao M, Yoshida T, et al.
N Engl J Med. 2020;383(18):1735-1745.
T-DXd
Gastric Cancer
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara K, Bang YJ, Iwasa S, et al.
N Engl J Med. 2020;382(25):2419-2430.
Edoxaban
Cardiovascular - AF
Cardiovascular - VTE
Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study
Colonna P, von Heymann C, Santamaria A, et al.
Clin Cardiol. 2020;43(7):769-780.
T-DXd
Breast Cancer
Colorectal Cancer
Gastric Cancer
Lung Cancer
Other/Multi
Targeting HER2 with trastuzumab deruxtecan: A dose-expansion, phase I study in multiple advanced solid tumors
Tsurutani J, Iwata H, Krop I, et al.
Cancer Discov. 2020;10(5):688-701.
T-DXd
Breast Cancer
Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study
Modi S, Park H, Murthy RK, et al.
J Clin Oncol. 2020;38(17):1887-1896.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi S, Saura C, Yamashita T, et al.
N Engl J Med. 2020;382(7):610-621.
Edoxaban
Cardiovascular - AF
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial
Vranckx P, Valgimigli M, Eckardt L, et al.
Lancet. 2019;394(10206):P1335-1343.
Quizartinib
Hematology
Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study
Takahashi T, Usuki K, Matsue K, et al.
Int J Hematol. 2019;110(6):665-674.
